Skip to content

#883: How to Legalize Medical Psychedelics in Your Country — Tania de Jong on The Playbook Behind Australia's World-First Breakthrough

The Tim Ferriss Show

Hosted by Tim Ferriss

2h 11m
Transcript

Original podcast

Summary

Written by a model from the transcript; not yet reviewed.

This episode features Tim Ferriss interviewing Tanya de Jong, co-founder of Mind Medicine Australia, about how they successfully led a campaign to make Australia the first country to allow the prescription of MDMA and psilocybin for psychiatric conditions in 2023. De Jong details her personal journey of trying psilocybin with her husband in Europe after reading Michael Pollan's work, which inspired them to establish Mind Medicine Australia. They explain the multi-pronged campaign strategy, which included building chapters across the country, training hundreds of clinicians, bringing international experts like David Nutt for national roadshows, and lobbying regulators. They also discuss the outcomes of the clinical rollout, where real-world data shows 60 to 80 percent remission rates for treatments costing between 15,000 and 25,000 Australian dollars. What makes this conversation worth listening to is the concrete playbook it offers for underdogs looking to create massive institutional change against long odds.

  • Pairing psilocybin with Syrian Rue can amplify visual and transcendental experiences significantly. 1:03:04
  • Real-world evidence collection is vital for demonstrating treatment efficacy and securing payer coverage. 1:34:10
  • Australia's regulatory shift has resulted in 60 to 80 percent remission rates for treated patients. 57:36

Chapters

  1. 0:42
    Early Psychedelic Inspiration

    Tania recounts how a 2015 article sparked her and her husband’s interest in psychedelic research.

  2. 5:01
    First Psychedelic Experience

    Tania and her husband’s first guided psilocybin session in the Netherlands and its transformative impact.

  3. 8:00
    Lobbying, Advisory Panel, and Key Allies

    Recruiting scientists, lobbyists, and high-profile allies like David Nutt to support the campaign.

  4. 10:00
    Rescheduling Victory and Clinic Rollout

    The 2023 rescheduling win, the opening of clinics, and the training of psychiatrists to prescribe psychedelics.

  5. 12:00
    Clinical Outcomes and Patient Impact

    Early treatment results, remission rates, and the broader societal implications for mental health care.

  6. 12:55
    Building Momentum and Training Clinicians

    The launch of Mind Medicine Australia, training 750 clinicians, and creating a national network of chapters.

  7. 14:00
    Integration Practices and Therapeutic Models

    Discussion of varied therapeutic modalities, integration support, and the importance of personalized care.

  8. 14:30
    Regulatory Hurdles and Public Campaign

    Repeated TGA rescheduling applications, public submissions, and a massive advocacy campaign that pressured regulators.

  9. 16:00
    Future Growth and Scaling Strategy

    Projected patient numbers, exponential growth of authorized prescribers, and plans for expanding access.

  10. 53:47
    Introduction and Context

    Tim Ferriss introduces the episode and outlines the focus on legalizing medical psychedelics in Australia.

  11. 1:13:27
    Mistakes and Lessons Learned

    MMAs reflect on early missteps, stakeholder pushback, and the importance of resilience in advocacy.

  12. 1:45:46
    Ketamine’s Pain Relief Potential

    Discussion of ketamine infusions for chronic pain and their surprising effectiveness.

  13. 1:46:51
    Global Shifts in Psychedelic Regulation

    Overview of upcoming regulatory changes worldwide, especially in Australia and the US.

  14. 1:47:34
    Australia’s Role in Clinical Trials

    Australia’s attractiveness as a location for international psychedelic research and its potential to reduce bureaucracy.

  15. 1:54:38
    Funding and Training Opportunities

    Details on Mind Medicine Australia’s fundraising goals and educational programs for clinicians.

  16. 1:55:30
    Advocacy Strategies and Persistence

    Tania shares tactics for persistent advocacy and lessons learned from pushing too hard.

Highlights

  • 4:02

    First Psilocybin Experience in Europestory

    De Jong describes her extreme anxiety prior to taking a large dose of psilocybin with a Dutch guide in Europe, having never taken any drugs previously.

  • 12:52

    Founding Mind Medicine Australiastory

    Following profound personal healing, De Jong and her husband founded Mind Medicine Australia in 2019 after speaking with Rick Doblin.

  • 14:18

    Targeting the TGA for Reschedulingstrategy

    Mind Medicine Australia submitted multiple applications to the Therapeutic Goods Administration to move MDMA and psilocybin from Schedule 9 to Schedule 8.

  • 39:08

    Presenting to the TGA Bureaucratsstory

    De Jong brought David Nutt and a grieving widow to present to 140 TGA employees, creating an emotional turning point for the regulatory committee.

  • 43:16

    Australia Reschedules Psychedelicsdata

    In February 2023, Australia officially rescheduled MDMA and psilocybin, making it the first country in the world to permit them for psychiatric prescription.

  • 46:56

    Clinical Remission Rates in Australiadata

    Data from early treatments across Australian clinics show 60 to 80 percent remission rates with no serious adverse events reported.

  • 1:31:29

    Clinic in a Box Modelstrategy

    Mind Medicine Australia partnered with a publicly traded company to launch a best-practice clinic in Melbourne to test treatment protocols and train clinicians.

Quotes

  • “In 2015, I came across your blog. Well, I'd been signing up to your blog for ages.”
    Unnamed speaker · 3:04
  • “And over 98% of people supported the rescheduling of these medicines.”
    Unnamed speaker · 16:03
  • “60 to 80% remission rates in Australia, which is replicating what we've seen in trials around the world.”
    Unnamed speaker · 46:56
  • “We just found out that now there's 120 authorized prescribing psychiatrists in Australia for either MDMA or psilocybin or both medicines.”
    Unnamed speaker · 52:55
  • “Because it could be a lot more, but maybe 5,000 is a realistic number. But that's a fraction of who needs it.”
    Unnamed speaker · 53:47
  • “We have no influence on, we simply fund it at the Australian National University, which collates real world evidence, the data from the baseline of a patient when they go in for the treatment, then what they're like when they come out of the treatment.”
    Unnamed speaker · 56:57
  • “We could save millions, tens of millions, hundreds of millions of dollars over the course of a patient's lifetime.”
    Unnamed speaker · 58:06
  • “The cost per patient, this was a few years ago already, could be well over a hundred thousand US dollars of cost savings.”
    Unnamed speaker · 1:00:07
  • “I actually had to, on several occasions, say to staff, 'Look, I know they're driving you crazy. Put their, put their approaches and the way they work to one side. Think about the medical criteria and the scientific criteria and the regulatory issues only.'”
    Tim Ferriss · 1:48:35
  • Momentous 17:00–18:04
  • ProLon 19:20–20:40
  • AG1 36:20–37:54
  • ProLon 2:08:29–2:09:50
  • Momentous 2:10:01–2:11:23

About this episode

My guest today is Tania de Jong https://www.taniadejong.com/, co-founder of Mind Medicine Australia https://mindmedicineaustralia.org.au/. Tania and her husband, Peter, helped lead the push that, in 2023, made Australia the first country in the world to allow MDMA and psilocybin to be prescribed for psychiatric conditions. I wanted to understand how the hell they helped make that happen and what the rest of the world can learn from it. This episode is brought to you by: ProLon https://prolonlife.com/Tim science-backed Fasting Mimicking Diet that helps activate cellular renewal through fasting, while still eating nourishing meals: https://prolonlife.com/TimMomentous https://livemomentous.com/Tim high-quality creatine for cognitive and muscular support: https://LiveMomentous.com/Tim https://LivemoMentous.com/TimAG1 https://drinkag1.com/tim all-in-one nutritional supplement: DrinkAG1.com/Tim https://drinkag1.com/timTimestamps [00:00:00] Intro from Tim. [00:02:46] The article that changed Tania’s life. [00:04:39] A first psychedelic experience—and the year it took to integrate it. [00:10:17] Rick Doblin’s encouragement and the birth of Mind Medicine Australia. [00:13:15] Turning regulatory rejection into a stronger application. [00:20:48] Building a grassroots movement and training clinicians. [00:23:23] Cold emails, scientific allies, and singing your way into the room. [00:31:11] A week with Ram Dass: silence, singing, and an extraordinary LSD story. [00:37:54] Bringing David Nutt—and a family’s devastating story—to the regulators. [00:42:42] Dancing in the kitchen: Australia’s rescheduling breakthrough. [00:43:40] From changing the rules to treating patients. [00:48:18] Why Tim thinks MDMA is still underestimated. [00:50:23] Integration beyond the session: therapy, nutrition, and exercise. [00:52:29] Scaling access and collecting real-world evidence. [00:58:13] Getting insurers, government agencies, and philanthropists on board. [01:00:44] Syrian rue, psilocybin, and learning to let go of control. [01:09:06] Dosing, expectations, and the pressure to take more. [01:11:07] The promise of group therapy and shared integration. [01:13:27] Hiring mistakes, personal attacks, and the resilience advocacy requires. [01:22:43] Turning a window of change into lasting habits. [01:24:56] Getting through to regulators and pushing for end-of-life access. [01:27:32] The bureaucratic barriers that remain. [01:30:43] What treatment costs—and why therapist time drives the bill. [01:34:12] Could shorter-acting compounds make treatment more affordable? [01:37:51] Ketamine, kratom, and the limits of “all natural.” [01:42:19] The unexpected payoff from Tim’s ketamine experiment. [01:46:51] What might come next for psychedelic access worldwide? [01:48:10] Persistence versus pushiness—and knowing when to try another door. [01:53:27] Supporting patients and training the next wave of clinicians. [01:56:56] “Be curious”: exploring your inner world and walking each other home. [02:00:40] The ripple effects of sharing your curiosity—and simply asking for help. Timeline: February 2, 2015: Michael Pollan publishes “The Trip Treatment https://www.newyorker.com/magazine/2015/02/09/trip-treatment” in The New Yorker, which is the article Tania credits with setting her journey in motion. March 21, 2015: Tim releases his James Fadiman interview, “The Psychedelic Explorer’s Guide https://tim.blog/2015/03/21/james-fadiman/” (#66). Its show notes link to “The Trip Treatment.”January 15, 2016: In 5-Bullet Friday, Tim announces support for Johns Hopkins’ psilocybin research and a personal commitment of at least $100,000 toward psychedelic research that year.2016: Tania and Peter travel to the Netherlands for their first guided psilocybin experience. (Source) https://www.taniadejong.com/wp-content/uploads/Songs-for-Psychedelics-A-Magic-Mushroom-Adventure-Press-Release-2021.pdf2017–2019: UCSF conducts the psilocybin-assisted group-therapy study involving long-term AIDS survivors that Tim helped support. (Source) https://pmc.ncbi.nlm.nih.gov/articles/PMC7599297/May 6, 2018: Michael Pollan joins Tim for “Exploring the New Science of Psychedelics” (#313), discussing his forthcoming book (How to Change Your Mind https://www.amazon.com/dp/0735224153?tag=offsitoftimfe-20). May 15, 2018: Pollan’s How to Change Your Mind https://www.amazon.com/dp/0735224153?tag=offsitoftimfe-20 is published. February 13, 2019: Tania and Peter publicly launch Mind Medicine Australia https://mindmedicineaustralia.org.au/. (Source) https://mindmedicineaustralia.org.au/understanding/2020–2022: MMA applies to reschedule MDMA and psilocybin, faces rejection, and submits new applications in March 2022. (Source) https://mindmedicineaustralia.org.au/wp-content/uploads/Media-Alert_MMA-response-to-Interim-Decision-2022-Release_FINAL_261022.pdfNovember 21, 2022: David Nutt presents to Australia’s medicines regulator, the TGA, supporting the case for therapeutic access. (Source) https://www.tga.gov.au/sites/default/files/2023-02/notice-of-final-decision-to-amend-or-not-amend-the-current-poisons-standard-june-2022-acms-38-psilocybine-and-mdma.pdfFebruary 3, 2023: The TGA announces restricted prescribing access to MDMA for PTSD and psilocybin for treatment-resistant depression, effective July 1, 2023. (Source) https://www.tga.gov.au/news/media-releases/change-classification-psilocybin-and-mdma-enable-prescribing-authorised-psychiatristsJanuary 2024: Patients begin receiving treatment under the new prescribing program. (Source) https://mindmedicineaustralia.org.au/treatments/* For show notes and past guests on The Tim Ferriss Show https://tim.blog/podcast, please visit tim.blog/podcast https://tim.blog/podcast/?utm_source=podcast&utm_medium=podcast&utm_campaign=podcast-description. For deals from sponsors of The Tim Ferriss Show https://tim.blog/podcast, please visit tim.blog/podcast-sponsors https://tim.blog/podcast-sponsors Sign up for Tim’s email newsletter (5-Bullet Friday) at tim.blog/friday https://go.tim.blog/5-bullet-friday-1/. For transcripts of episodes, go to tim.blog/transcripts https://tim.blog/transcripts. Discover Tim’s books: tim.blog/books https://tim.blog/books. Follow Tim: Twitter: twitter.com/tferriss https://twitter.com/tferriss Instagram: instagram.com/timferriss https://instagram.com/timferriss/ YouTube: youtube.com/timferriss https://www.youtube.com/timferriss Facebook: facebook.com/timferriss https://www.facebook.com/TimFerriss/ LinkedIn: linkedin.com/in/timferriss http://linkedin.com/in/timferriss See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Transcript

0:00
2:11:33

22,495 words · 3 speakers

Speaker names marked are inferred from speaking time and the show’s known hosts — they are not voice-verified.

Topics

  • Australia
  • psilocybin
  • TGA
  • MDMA
  • MAPS
  • Therapeutic Goods Administration
  • USONA
  • Medibank
  • Wisconsin
  • Melbourne

Page updated · transcript and summary are machine-generated